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Current Opinion in
Structural BiologyGut power: Modulation of human amyloid formation by
amyloidogenic proteins in the gastrointestinal tract
Pernilla Wittung-StafshedeAbstract
Protein assembly into amyloid fibers underlies many neuro-
degenerative disorders. In Parkinson’s disease, amyloid for-
mation of a-synuclein is linked to brain cell death. The
gut–brain axis plays a key role in Parkinson’s disease, and
initial a-synuclein amyloid formation may occur distant from the
brain. Because different amyloidogenic proteins can cross-
seed, and a-synuclein is expressed outside the brain, amyloids
present in the gut (from food products and secreted by
microbiota) may modulate a-synuclein amyloid formation via
direct interactions. I here describe existing such data that only
began to appear in the literature in the last few years. The
striking, but limited, data set—spanning from acceleration to
inhibition—calls for additional investigations that may unravel
disease mechanisms as well as new treatments.
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Today we know of many human diseases, often involving
neurodegeneration, that are based on protein aggregation
into amyloid fibers [1]. Amyloid fibers all share a
common cross-b structure [2], but they can be formed by
numerous different proteins with different starting
structures. Parkinson’s disease (PD) [3,4] is the second
most common neurodegenerative disorder, after
Alzheimer’s disease, among those involving amyloid fibrilwww.sciencedirect.comformation. The number of patients in the world with
neurodegenerative disorders, such as PD, is increasing,
but we have no cures: there are only symptomatic drugs
that provide temporary reliefs. PD is characterized by
widespread deterioration of dopaminergic neurons in the
substantia nigra. The molecular pathology of PD is
directly linked to the assembly of the protein a-synu-
clein (aS) into amyloid fibrils; such aS amyloids are the
major components of pathological inclusions, so-called
Lewy bodies, found in brains of patients with PD [5].
The 140-residue aS monomer, intrinsically disordered in
solution but helical when bound to lipid vesicles, is
believed to function in vesicle fusion and transport in
presynaptic nerve termini [6]. Aberrant assembly of aS
monomers to amyloid fibers is thought to be a toxic
process that is coupled to mitochondrial dysfunction,
oxidative stress, protein degradation failure, and even-
tually cell death [7]. Soluble aS oligomers have been
proposed to be most dangerous [8], but studies have also
demonstrated that amyloid fibrils are toxic and can be
transmitted from cell to cell [9,10]. Recent in vitro re-
sults showed that oligomers are not only intermediates
on the path to amyloid fibers; preformed aS amyloid
fibers can also release oligomeric species that are toxic to
neurons [11]. An important yet unanswered question is
what cellular processes, imbalances, or external species
initiate the cascade of deleterious reactions that result in
amyloid formation and neurodegeneration. In this
respect, it is important to point out that in addition to
neuronal cells, aS is expressed in many cell types in the
body including enteroendocrine cells (EECs) of the gut
epithelium. The latter is perhaps most relevant as the
gutebrain axis has been emphasized as a central ‘high-
way’ in the spreading of PD.The role of the gut in PD
It was recently speculated that the gut microbiome can
initiate as well as modulate PD [12,13], and studies
have indicated roles for the gastrointestinal tract and the
enteric nervous system (ENS) [14] (Figure 1). ENS
neurons are found in the walls of the gastrointestinal
tract and connect directly with EECs which, in turn,
communicate with the gut content. Recent studies have
shown that Lewy bodies are often observed in ENS
neurons in early stages of PD, introduction of preformed
aS amyloid fibers in the gastrointestinal tract of mice
induces Lewy body formation in the brain [15], and theCurrent Opinion in Structural Biology 2022, 72:33–38
Figure 1
Illustration of the gut–brain axis. The enteric nervous system (ENS)
connects the brain, where amyloid deposits are found in, for example,
Parkinson’s disease, with the gastrointestinal tract. Note that the ENS
extends from the esophagus all the way to the anus (here hidden in view
by the gastrointestinal tract). Both nondegraded food amyloids and am-
yloids secreted by the microbiome may interact with human amyloido-
genic proteins in neuronal cells connected to the gut. The picture was
made with BioRender.com.
34 Folding and Bindingrisk of PD was drastically reduced for patients with
truncal vagotomy [16].
Although the molecular determinants are unknown
[17], studies have shown that amyloids of one protein
can cross-seed other amyloidogenic proteins, both
among different human proteins [18] and between
human and nonhuman amyloidogenic proteins [19**].
The latter is interesting with respect to the gut, as the
microbiome contains several bacteria that secrete amy-
loids as part of their biofilms and food products some-
times contain amyloids (Figure 1). Several food proteins
that act as allergens (such as whey and casein proteins in
milk, ovalbumin and lysozyme in egg, and b-parvalbu-
min in fish) adopt amyloid states that confer protection
against gastrointestinal digestion and allow uptake in
the body [20]*. One may imagine that nonhuman
amyloids in the gut may cross-react and trigger amyloid
formation of aS in nearby cells that then transfer to the
brain or that bacterial/food amyloids themselves travel
via blood or the ENS to the brain and interact with aS
polypeptides there. After a first section on the link to
the innate immune system, I will summarize the current
knowledge of direct interactions between aS and amy-
loids from bacteria and diet that can be found in the gut,Current Opinion in Structural Biology 2022, 72:33–38as well as how such cross-reactivity affects aS amyloid
formation kinetics in vitro (Table 1). Although there are
only a few such studies reported to date, key discoveries
have been made.Modulations via the immune system
In addition to activities in brain function, aS is thought
to be a player in the innate immune system. In response
to viral and bacterial infections, ENS cells trigger
increased expression of aS [21]. Microbes and viruses
reaching the gut via the diet, or other insults to the gut,
may thus promote aS overexpression in the ENS as a
protective immune response. However, this may result
in aS amyloid formation because of high local protein
concentration, perhaps coupling with defective protein
aggregate clearance. aS amyloids formed in the ENSmay
then travel to the brain and trigger PD. Most nonhuman
amyloid structures can trigger an immune response that
leads to weakening of the gut barrier [22]. In addition,
aging, a major risk factor for PD, increases the perme-
ability of the intestine [23]. Such changes will allow for
increased uptake of nonhuman amyloids (and other
bacterial and viral diet components) from the gut that
can then promote PD (and amyloid formation) in at
least two ways: via an immune response that upregulates
aS expression and by direct interactions (in EECs or the
ENS) between the nonhuman proteins and aS [24].Cross-reactivity with microbiome
amyloidogenic proteins
Many microorganisms produce extracellular biofilms
that help the organism to adhere to surfaces, for
example, in the gastrointestinal tract [25,26]. Such
biofilms contain amyloid fibers, and in Escherichia coli and
other bacteria, CsgA is the protein that assembles to
amyloids (often called curli) [27]. The bacterial genome
codes for several accessory proteins that control the
production of curli fibers and assure they only form
extracellularly [28]. CsgA contains five peptide repeat
units, each predicted to form a b-loop-b motif, that are
proposed to constitute the core of the amyloid fibers
[29]. An initial study showed that when rats were fed
curli-producing E. coli, there was an increase in aS am-
yloid formation as compared with animals that had been
fed curli-deficient E. coli [13]. In subsequent work, it
was observed that the bacterial composition of the
microbiome, and/or products produced by the bacteria,
in aS-expressing mice could increase aS brain deposits,
neuroinflammation, and motor deficits [12]. Thus, al-
terations in the microbiome appear as a risk factor for
PD. To search for a possible molecular mechanism that
involved direct cross-reactivity, in vitro experiments with
purified CsgA and aS were executed [30**]. Not only
did CsgA preformed amyloids accelerate aS amyloid
formation but also the monomeric form of CsgA at sub-
stoichiometric amounts (at low enough concentration
such that CsgA alone did not aggregate) accelerated aSwww.sciencedirect.com
Table 1
Consequences for in vitro aS amyloid formation on interaction with nonhuman amyloidogenic proteins that may be found as amyloids in
the gut.
Protein Source Structure Effect Year Reference
CsgA E. coli Acceleration 2020 [30]
FapC Pseudomonas No effect 2019 [32]
FapC truncation Inhibition 2019 [32]
b-parvalbumin Fish Inhibition 2018 [36]
Lysozyme Egg Acceleration 2021 [38]
b-lactoglobulin Milk No effect 2021 [38]
While CsgA and FapC are unstructured polypeptides that readily assemble to amyloids, b-parvalbumin, lysozyme, and b-lactoglobulin have globular
structures when functional.
Cross-reactivity between gut and human amyloids Wittung-Stafshede 35amyloid formation in vitro. Because the amount of added
CsgA was sub-stoichiometric, a catalytic mechanism
involving transient interactions was proposed, and this
conclusion agreed with lack of stable interactions found
in surface plasmon resonance binding experiments
[30**]. The cross-reactivity between CsgA and aS
depended on CsgA’s amyloid-forming ability as aS-
expressing mice mono-colonized with E. coli bacteria
which produced an amyloid-deficient CsgA protein (or
mice injected with nonamyloidogenic CsgA) did not
show much aS aggregation and had less motor
impairment as compared with mice with wild-type CsgA
[30**]. Interestingly, two curli operon proteins acting as
chaperones for CsgA inside cells (CsgC and CsgE) also
affected aS amyloid formation: CsgC accelerated,
whereas CsgE inhibited, aS amyloid formation via
differential transient interactions with the C-terminal
of aS [31].Like CsgA, Pseudomonas aeruginosa FapC assembles into
amyloids that provide structural stability to the biofilm,
but this protein has only three amyloid-promoting
peptide repeat units. To elucidate the role of these
repeat units in FapC amyloid formation, various variants
of FapC were characterized in vitro. Surprisingly, it waswww.sciencedirect.comfound that despite removal of all repeats, the protein
still formed amyloids, albeit slower. The delay in amy-
loid formation kinetics allowed for disulfide-bond for-
mation between cysteine residues in FapC monomers,
which in turn delayed the aggregation process further
[32**]. Like E. coli, Pseudomonas is abundant in the gut
[33], and cross-reactivity between FapC and aS was
tested in vitro. In contrast to CsgA, preformed amyloids
of neither wild-type nor mutant FapC affected aS am-
yloid formation [32**]. However, the slower-aggregating
variant of FapC was found to interact with aS (at
monomeric or oligomeric states) in a process that
retarded aS amyloid formation in vitro; instead, dead-end
oligomers containing both proteins were detected
[32**].Cross-reactivity with food protein amyloids
The most common allergen in fish, the highly abundant
protein b-parvalbumin (PV), forms amyloids that escape
gastrointestinal degradation and transit to the blood
[34,35]. PV is a small, calcium-binding protein with a
helical structure that transforms to amyloids on calcium
removal. Because fish is generally considered beneficial
toward age-related diseases such as dementia and
Alzheimer’s disease, we speculated that an explanationCurrent Opinion in Structural Biology 2022, 72:33–38
Figure 2
Scheme showing reported consequences (inhibition or acceleration) on
a-synuclein amyloid formation in vitro upon direct interactions with food
(fish b-parvalbumin and egg lysozyme) and bacterial (E. coli CsgA and
Pseudomonas FapC variant) amyloidogenic proteins. (Milk b-lactoglobulin
amyloids, also tested, had no effect.) The picture was made with
BioRender.com.
36 Folding and Bindingwould be cross-reactivity of PV amyloids with human
amyloidogenic proteins [36**]. Indeed, in vitro experi-
ments showed that PV amyloids readily blocked aS
amyloid formation. It was revealed that PV amyloids,
perhaps via their protruding negatively charged calcium-
binding loops, scavenged aS monomers to the PV amy-
loid surface. Immunogold staining experiments showed
PV amyloids to be covered with aS [36**]. However, on
calcium addition to such systems, with the calcium
likely binding to the protruding loops on the PV amy-
loids, aS was released from the PV amyloids and started
to aggregate. In addition to cross-reactivity, the experi-
ments demonstrated that only primary (i.e. not sec-
ondary nucleation or fragmentation) processes are
involved in PV amyloid formation, and on further
investigation, the amyloid formation mechanism was
shown to involve on-path disulfide bridged dimers [37]
*. Notably, inhibition of amyloid formation via scav-
enging of monomers to a preformed amyloid of a
different protein is a new inhibition mechanism not
reported before.
In addition to fish, other food products contain protein
amyloids that are not fully digested in the gut: for
example, whey and casein proteins (milk), ovalbumin,
lysozyme and ovotransferrin (egg), bovine serum albu-
min and hemoglobin (blood), and glutelin (wheat) [20].
However, there are few cross-reactivity studies between
such proteins and human amyloidogenic proteins. In a
recent study, it was shown that amyloids of egg lyso-
zyme, but not amyloids of bovine b-lactoglobulin,
accelerated aS amyloid formation in vitro. For lysozyme,
the authors demonstrated a surface-mediated seeding
mechanism that depended on favorable electrostatic
interactions between aS and lysozyme [38**].Conclusions and outlook
Microbial and food amyloids can modulate aS amyloid
formation via direct interactions, and this type of cross-
reactivity, in addition to immune system effects, may
contribute to the gutebrain ‘highway’ in PD (Figure 2).
In addition to Escherichia and Pseudomonas already
mentioned when discussing CsgA and FapC, Strepto-
coccus, Staphylococcus, Salmonella, Mycobacteria, Klebsiella,
Citrobacter, and Bacillus bacterial species (and many
others) are found in the gut, and these also make extra-
cellular amyloids. Although little is known about the
abundance of different bacterial amyloids because of
extensive variability of composition from person to
person, it is important to note that for cross-seeding, only
small amounts of seeds are needed. Food amyloids will
likely become more common in the future as amyloid
structures have favorable foaming, emulsifying, and gel
properties that improve food texture [39]. Proteins
forced into amyloid structures can be used, for example,
as thickening ingredients, surface active media, carriers
for nutrients and drugs, packaging materials, andCurrent Opinion in Structural Biology 2022, 72:33–38antimicrobial substances. Most proteins in our diet are
digested to amino acids in the gut, but studies show that
amyloids can be resistant to gastric conditions [39].
Before using amyloids in food production, one should
assess possible toxicity case by case. Amyloidogenic
proteins in food that escape degradation may both
accelerate and inhibit human amyloidogenic proteins.
Moreover, food amyloids may cross-react with biofilm
amyloids and thereby affect the microbiota composition.
Many more in vitro experiments with purified proteins
that probe direct interactions between human and gut
amyloidogenic proteins are desired. Knowledge of such
interactions and consequences in vitro will complement
in vivo studies that, when taken together, may reveal
underlying (causative) reasons for the onset of human
amyloid diseases such as PD, as well as unravel novel
avenues toward treatments supplied via the gut.Notably,
there are already clinical trials showing promising results
for orally administered drugs (e.g. squalamine and levo-
dopa) that appear to modulate aS aggregation and prop-
agation in the ENS [21,40]. In fact, several aminosterol
derivatives, such as squalamines and trodusquemine, are
currently explored as modulators of cell membrane
physicochemical properties [41,42]. The therapeutic
strategy here is to stabilize cell membranes (possibly in
the ENS) so they become resistant to perturbations by
protein aggregates (e.g. aS oligomers and amyloids)
associated with neurodegeneration.
I want to end with a timely connection to the COVID-
19 pandemic. It has been proposed that a peptide from
the COVID-19 spike protein, created during viruswww.sciencedirect.com
Cross-reactivity between gut and human amyloids Wittung-Stafshede 37processing, can assemble into amyloids. Because
COVID-19 may infect the gut [43] in addition to the
lungs and other organs, cross-reactivity between this
virus-derived amyloid and human amyloidogenic pro-
teins in the gut may underlie observed post-infection
neurodegenerative symptoms [44]*.Conflict of interest statement
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